Adverum Biotechnologies (ADVM) Misses Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Adverum Biotechnologies (ADVM) Misses Q3 EPS by 5c

Adverum Biotechnologies Reports Third Quarter 2022 Financial Results

November 10, 2022 4:05 PM EST

- First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023

- Cash runway into 2025 prioritizing Ixo-vec clinical development in wet age-related macular degeneration (wet AMD)

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced financial results for the third quarter ended September 30, 2022.

The third quarter... More